Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Published Date: 02 May 2026

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Read Full News

Latest News

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Todays Updates

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Todays Updates

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Latest News

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

News All Time

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Radioligand Therapy Set to Transform Oncology Care

Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Oncology Care Model’s Net Losses Well Exceed Savings

But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Recommended News For You

Schizophrenia patients are motivated by music therapy.

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

Exercise can counter detrimental effects of cancer treatment, review suggests

finding fresh approaches to treating diffuse midline gliomas.

Which Risk Model Better Identifies High-Risk Smoldering MM?

Recommended Articles For You

Acrochordon: What It Is, Causes, And How To Manage This Skin Condition 

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 

What is Red Cell Distribution Width and Why Should You Care? 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Many Americans unaware of links between HPV and cancers, poll reveals

2.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

3.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

4.

Cancer during young adulthood carries long-term mental toll, study finds

5.

Exercise can counter detrimental effects of cancer treatment, review suggests

1.

The New Era of Oncology: Key Updates and Clinical Insights

2.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

3.

What Is Degos Disease? A Comprehensive Overview Of Symptoms, Diagnosis, and Treatment

4.

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management

5.

How EPCORITAMAB is Revolutionizing the Treatment of Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part II

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

4.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

5.

Navigating the Complexities of Ph Negative ALL - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot